
Bristol Myers: meeting with FDA on Opdivo
(CercleFinance.com) - Bristol Myers has announced that the US FDA will hold a public meeting of the Oncology Drug Advisory Committee (ODAC) on 26 September 2024.
As part of this meeting, Bristol Myers Squibb will meet with the Committee to discuss approved indications in the US for Opdivo (nivolumab)-based combinations in gastric cancer (GC), gastroesophageal junction cancer (GJEC) and esophageal adenocarcinoma (EoA), as well as esophageal squamous cell carcinoma (ESC).
We look forward to discussing in more detail with the Committee the importance of Opdivo-based regimens as treatment options for appropriate patients with gastric and esophageal cancers, Bristol Myers Squibb said.
Note that Opdivo, in combination with fluoropyrimidine and platinum-based chemotherapy, received full FDA approval for the treatment of adult patients with advanced or metastatic GC, GCOC and AO in 2021.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
As part of this meeting, Bristol Myers Squibb will meet with the Committee to discuss approved indications in the US for Opdivo (nivolumab)-based combinations in gastric cancer (GC), gastroesophageal junction cancer (GJEC) and esophageal adenocarcinoma (EoA), as well as esophageal squamous cell carcinoma (ESC).
We look forward to discussing in more detail with the Committee the importance of Opdivo-based regimens as treatment options for appropriate patients with gastric and esophageal cancers, Bristol Myers Squibb said.
Note that Opdivo, in combination with fluoropyrimidine and platinum-based chemotherapy, received full FDA approval for the treatment of adult patients with advanced or metastatic GC, GCOC and AO in 2021.
Copyright (c) 2024 CercleFinance.com. All rights reserved.